Revolutionizing AFib Treatment: The Rise of Pulsed Field Ablation
Originally Published 1 year ago — by Star Tribune
Medtronic, Boston Scientific, and Johnson & Johnson MedTech are racing to commercialize pulsed field ablation (PFA) technology, a safer and quicker treatment for atrial fibrillation (AFib). PFA uses electric pulses to ablate cardiac tissue, reducing procedure time and complications compared to older methods. The technology is expected to drive significant growth in the medtech industry, with global sales projected to surpass $1.3 billion. The new systems, including Boston Scientific's Farapulse and Medtronic's PulseSelect, have received FDA approval, marking a shift in AFib treatment.